Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

CRISPR Therapeutics AG - Common Shares (NQ: CRSP )

42.91 +0.92 (+2.19%)
Streaming Delayed Price Updated: 9:35 AM EDT, Mar 14, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about CRISPR Therapeutics AG - Common Shares

< Previous 1 2
...
9 10 11 12 13 14 15 16 17
...
31 32 Next >
One Month Ahead of its Most Crucial Moment Ever, Should You Buy CRISPR Therapeutics?
This stock could be a long-term winner, thanks to its game-changing technology. 
Via The Motley Fool
Why Are Stocks Up Today?
Stocks are up today as investors prepare for the most recent information from the Federal Reserve concerning interest rates. 
Via InvestorPlace
Topics Economy
Exposures Interest Rates
Why Is Aldeyra Therapeutics (ALDX) Stock Up 40% Today?
Aldeyra Therapeutics stock is rising with heavy trading of ALDX shares after signing an exclusive option agreement with AbbVie. 
Via InvestorPlace
Crispr Therapeutics Rallies On Bullish Views Of First-Ever Gene-Editing Drug
The agency could soon approve a potential cure for sickle cell disease . 
Via Investor's Business Daily
CRSP Stock Alert: Can CRISPR Therapeutics Short Squeeze Higher?
CRSP stock is rallying after an FDA panel appeared to view CRISPR Therapeutics' sickle-cell anemia treatment as safe. 
Via InvestorPlace
Exposures Product Safety
AMD, CRISPR Therapeutics, Paycom Software, DraftKings, Tesla: Why These 5 Stocks Are On Investors' Radars Today
Major U.S. indices ended in the green on Tuesday, with the Dow gaining nearly 124 points or 0.4% to 33,052.87. 
Via Benzinga
Topics Stocks
Exposures US Equities
CRISPR Therapeutics Stock: Bull vs. Bear
Here's the scoop on one of the most widely followed gene-editing stocks on the market. 
Via The Motley Fool
CRSP Stock Halt: CRISPR Trading Halted Ahead of FDA Decision
Investors in CRISPR and CRSP stock have certainly been on a wild ride so far this year. Here's what investors need to watch right now. 
Via InvestorPlace
Exposures Product Safety
Gene Therapy Could Be On the Cusp of a Major Breakthrough, but Investors May Have to Remain Patient
This gene-editing pioneer could make history this week. But shareholders should remain focused on the long term. 
Via The Motley Fool
CRSP Stock: FDA Considers Additional Review of CRISPR Therapeutics Gene Therapy
Although CRISPR Therapeutics may have a breakthrough drug on its hands, regulatory concerns hang over CRSP stock. 
Via InvestorPlace
Exposures Product Safety
Questions Surround Vertex/CRISPR's Sickle Cell Gene Therapy As FDA AdComm Meeting Approaches
The FDA's Cellular, Tissue, and Gene Therapies Advisory Committee will meet next  
Via Benzinga
Exposures Product Safety
Vertex Pharmaceuticals: Buy at the High?
Vertex shares have been flying high in recent times. 
Via The Motley Fool
2 Fantastic Growth Stocks to Buy Hand Over Fist
These stocks make great bargains today. 
Via The Motley Fool
2 Biotech Stocks You Can Buy and Hold for the Next Decade
Neither has performed well on the stock market this year. 
Via The Motley Fool
3 No-Brainer Stocks to Buy Right Now for Less than $100
You can start with a small investment and win big over time. 
Via The Motley Fool
7 Biotech Stocks to Get In Now Before Investors Catch On
Biotech stocks are down, but there are hidden gems among the rubble. Get in now before the broader market finds them. 
Via InvestorPlace
Cathie Wood Is Buying These Top Growth Stocks -- and Both Could Make You Richer Over Time
Wood is going all in on gene editing. 
Via The Motley Fool
3 Gene Editing Stocks to Generate Super-Charged Gains
As things progress, such techniques may be able to knock out every disease known, creating massive opportunity for gene-editing stocks. 
Via InvestorPlace
Intellia Stumbles As It Aims For A First-Ever In CRISPR Gene Editing
The company can begin a pivotal study of its treatment for cardiomyopathy. 
Via Investor's Business Daily
Cathie Wood-Led Ark Invest Sells Over $6.5M Worth Of Tesla Stock, What's Going On?
Via Benzinga
Cautious Optimism For Bluebird Bio's Sickle Cell Therapy: Analyst Sees Financial Challenges
Cantor Fitzgerald initiated coverage on Bluebird Bio Inc (NASDAQ: BLUE), saying sickle cell disorder (SCD) has been a hotbed of development for genetic medicines as the company's lovo-cel marches... 
Via Benzinga
Editas Medicine Has To Navigate Sickle Cell Therapy Competition: Analyst
Cantor Fitzgerald has downgraded Editas Medicine Inc (NASDAQ: EDIT) to Neutral from Overw 
Via Benzinga
Mixed Signals For CRISPR Therapeutics, Analyst Weighs Barriers, Potential Sales For Sickle Cell Therapy
Cantor Fitzgerald has downgraded CRISPR Therapeutics AG (NASDAQ: CRSP) to Neutral from Ov 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For October 17, 2023
Via Benzinga
This Cathie Wood Stock Is Set to Soar 100%, Says Wall Street
This Wood favorite is heading for a big moment. 
Via The Motley Fool
2 Growth Stocks That Could Double Your Money, According to Wall Street
Find out why investment bank analysts are pounding the table on these stocks. 
Via The Motley Fool
2 Growth Stocks That Could Deliver Parabolic Returns in Under 5 Years
These two gene-editing stocks could be diamonds in the rough. 
Via The Motley Fool
Cathie Wood's Ark Invest Sells $9.8M Worth Of Tesla Shares — Second Day Of Selling EV Giant In A Row
Via Benzinga
Cathie Wood's Ark Invest Keeps On Cutting Tesla Holdings, Sells More Than $8M Worth Of EV Maker's Shares
Via Benzinga
Cathie Wood Is Buying CRISPR Therapeutics Ahead of This Big Event. Should You?
Wood has outperformed the market so far this year. 
Via The Motley Fool
< Previous 1 2
...
9 10 11 12 13 14 15 16 17
...
31 32 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.